Related references
Note: Only part of the references are listed.Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
Henriette Huber et al.
BLOOD (2022)
Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia
Giovanni D'Arena et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2022)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Xin Victoria Wang et al.
BLOOD (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples
Laiz Bento et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
Timothy W. Farren et al.
FRONTIERS IN ONCOLOGY (2020)
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Philip A. Thompson et al.
BLOOD (2019)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL
Niamh Appleby et al.
LEUKEMIA & LYMPHOMA (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
A. C. Rawstron et al.
LEUKEMIA (2016)
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
Gabor Kovacs et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry
Anita K. Dowling et al.
LABORATORY MEDICINE (2016)
Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry
Anita K. Dowling et al.
LABORATORY MEDICINE (2016)
ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL)
Michaela Patz et al.
BLOOD (2016)
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
Nicholas J. Short et al.
CANCER (2015)
Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
T. W. Farren et al.
BLOOD CANCER JOURNAL (2015)
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
Olga Frankfurt et al.
LEUKEMIA & LYMPHOMA (2015)
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy
Rodrigo Santacruz et al.
HAEMATOLOGICA (2014)
Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice
O. Stehlikova et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia
M. M. Sartor et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
A. C. Rawstron et al.
LEUKEMIA (2013)
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
A. C. Rawstron et al.
LEUKEMIA (2007)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
